Antisense Oligonucleotides against Cancer Cell Migration and Invasion
Summary:
NCI is seeking parties interested in co-developing and/or licensing therapeutic antisense oligonucleotides that target cell migration and cancer metastasis.
Humanized Mouse Model to Study Mesothelin (MSLN) -targeted Cancer Therapeutics: Bl6/TPO Mice
Summary:
The NCI Laboratory of Molecular Biology is seeking parties interested in licensing a genetically engineered mouse model expressing hMSLN in the thyroid gland for commercialization in the field of cancer therapeutics and research targeting mesothelin-expressing tumors.
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Summary:
The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies.
Description of Technology:
CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.
CD206 Small Molecule Modulators, Their Use and Methods for Preparation
Summary:
The NCI is seeking licensing partners and/or collaborators to perform IND enabling studies to translate the anti-CD206 small molecule into a therapeutic for CD206 expressing cancers.
Gene Therapy for Treatment of CRX-Autosomal Dominant Retinopathies
Description of Technology:
Mutations in the cone rod homeobox (CRX) transcription factor lead to distinct retinopathy phenotypes, including early-onset vision impairment in dominant Leber congenital amaurosis (LCA). Adeno-Associated virus (AAV) vector-mediated delivery of a CRX cDNA under the control of a CRX promoter region partially restored photoreceptor phenotype and expression of phototransduction genes in an in vitro model of CRX-LCA.
T-cell Receptors Targeting CD20-Positive Lymphomas and Leukemias
Summary:
NCI seeks parties interested in licensing to further develop a collection of novel anti-CD20 TCRs that can be used to treat CD20 positive lymphomas and leukemias.
Denoising of Dynamic Magnetic Resonance Spectroscopic Imaging Using Low Rank Approximations in the Kinetic Domain
Summary:
The scientists seek co-development parties and/or licensees for a method for measuring low-abundance metabolites in vivo.
Use of Cucurbitacins and Withanolides for the Treatment of Cancer
Description of Technology:
Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death receptor-4 (DR4 or TRAIL-R1) and death receptor 5 (DR5, TRAIL-R2).
Novel Regulatory B cells for Treatment of Cancer and Autoimmune Disease
Description of Technology:
The manner by which cancers evade the immune response is not well-understood. What is known is that the manner is an active process that regulates immune responses employing at least two types of suppressive cells, myeloid-derived suppressive cells and regulatory T cells (Tregs), a key subset of CD4+ T cells that controls peripheral tolerance to self- and allo-antigens. Tregs are considered to play a key role in the escape of cancer cells from anti-tumor effector T cells.
Margaric Acid Decreases PIEZO2 Mediated Pain
Summary:
The National Center for Complimentary and Integrative Health (NCCIH) seeks licensees and/or commercial partners to develop topical formulations of margaric acid to treat allodynia, neuropathy, and pain caused by chronic inflammation.